Finding Balance: New Strategies to Optimize Care for Patients With Parkinson’s Disease Psychosis
This activity is jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC.
This activity is supported by an independent educational grant from ACADIA Pharmaceuticals LLC
After reading this CME supplement, health care providers will have improved their ability to:
Discuss the clinical features and risk factors for Parkinson's disease psychosis (PDP)
Develop individualized pharmacologic treatment plans for patients with PDP that consider motor and nonmotor symptoms
Evaluate the mechanism of action, tolerability, safety, and efficacy of pharmacologic treatment options for PDP
Employ multidisciplinary communication strategies to improve quality of life in patients with PDP
This CME supplement entitles the reader to 1.0 AMA PRA Category 1 Credit™ Click here to read supplement. After reading the supplement, click here to access the CME posttest
This activity is jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC.
This activity is supported by an independent educational grant from ACADIA Pharmaceuticals LLC
After reading this CME supplement, health care providers will have improved their ability to:
Discuss the clinical features and risk factors for Parkinson's disease psychosis (PDP)
Develop individualized pharmacologic treatment plans for patients with PDP that consider motor and nonmotor symptoms
Evaluate the mechanism of action, tolerability, safety, and efficacy of pharmacologic treatment options for PDP
Employ multidisciplinary communication strategies to improve quality of life in patients with PDP
This CME supplement entitles the reader to 1.0 AMA PRA Category 1 Credit™ Click here to read supplement. After reading the supplement, click here to access the CME posttest
This activity is jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC.
This activity is supported by an independent educational grant from ACADIA Pharmaceuticals LLC
After reading this CME supplement, health care providers will have improved their ability to:
Discuss the clinical features and risk factors for Parkinson's disease psychosis (PDP)
Develop individualized pharmacologic treatment plans for patients with PDP that consider motor and nonmotor symptoms
Evaluate the mechanism of action, tolerability, safety, and efficacy of pharmacologic treatment options for PDP
Employ multidisciplinary communication strategies to improve quality of life in patients with PDP
This CME supplement entitles the reader to 1.0 AMA PRA Category 1 Credit™ Click here to read supplement. After reading the supplement, click here to access the CME posttest
